Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nitroxoline - Asieris Pharmaceuticals

Next Previous
Drug Profile

Nitroxoline - Asieris Pharmaceuticals

Alternative Names: APL-1202; Vesique

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Johns Hopkins University
  • Developer Asieris Pharmaceuticals
  • Class Antibacterials; Antifungals; Antineoplastics; Antiprotozoals; Hydroxyquinolines; Nitroquinolines; Small molecules
  • Mechanism of Action Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II Amoebiasis
  • No development reported Prostate cancer

Most Recent Events

  • 28 Aug 2026 Asieris Pharmaceuticals receives authorisation from Health Canada for Nitroxoline in Free-living Amoebae Infections prior to August 2026
  • 06 Aug 2026 Phase-II clinical trials in Amoebiasis in China (PO) (Asieris Pharmaceuticals pipeline, August 2026)
  • 18 Apr 2025 Efficacy data from phase-I/II ANTICIPATE trail in Bladder cancer released by Asieris Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top